- Obama’s regulatory agenda will cost U.S. economy $143B next year: report
- Patriot Act author on James Clapper: Fire, prosecute him
- Russia P.M. Medvedev: No amnesty for political prisoners
- Michigan GOP Senate hopeful reminds government is the ‘servant’
- Christmas, by Congress: Members mull a 15-cent tax on trees
- U.S. unemployment falls to five-year low of 7 percent; 203K jobs added
- World mourns Nelson Mandela and celebrates his life; burial set for Dec. 15
- Bill O’Reilly reminds: Nelson Mandela ‘was a communist’
- John Boehner says GOP should support gay candidates: ‘I do’
- Grass-Whopper: Pan-fried cricket burgers go over big in New York City
Highly anticipated weight-loss pill wins approval
Question of the Day
The FDA initially rejected Vivus’ drug in 2010 over concerns that it can cause birth defects if taken by pregnant women. The agency laid out a risk-management plan Tuesday specifically designed to minimize the chance of the women becoming pregnant while using the drug. It recommends that women of childbearing age test negative for pregnancy before starting the drug and take a monthly pregnancy test while taking it.
The agency also said patients with recent or unstable heart disease or stroke aren’t good candidates for the drug because its effect on heart rates in those patients is not known. Vivus has to do studies of the heart effects of Qsymia, the FDA said.
Analysts estimate the new pill could garner more than $1 billion in sales by 2016, though Mountain View, Calif.-based Vivus plans a slow rollout.
The pill will launch with a relatively small sales force of 150 representatives. Company executives say their initial marketing efforts will focus on obesity specialists, not general doctors.
“We’re going to have to grow our sales organization in order to support the primary care market,” Vivus President Peter Tam said in an interview with the Associated Press.
Vivus had originally planned to market the drug under the brand name Qnexa. However, FDA regulators ordered the company to change the name to avoid potential confusion with similar-sounding drugs.
Rival Arena Pharmaceuticals Inc. of San Diego plans to start selling Belviq early next year. A third California drugmaker, Orexigen Therapeutics Inc., is still running clinical trials of its product, Contrave, and is working toward an FDA approval date in 2014.
- Obama administration issues permits for wind farms to kill more eagles
- Spike in battlefield deaths linked to restrictive rules of engagement
- Rush Limbaugh: Obama trying to make Mandela death about himself
- Bill OReilly reminds: Nelson Mandela was a communist
- PRUDEN: British press horrified as London's new mayor dares to proclaim the truth
- Federal deficit shrinks 20 percent in fiscal 2014
- EDITORIAL: Our ideological president
- Activists urge Obama to go rogue, sidestep Congress
- Chris Matthews: GOP less patriotic than South African white apartheid leaders
- Sen. Rand Paul pushes 'Economic Freedom Zones' for Detroit
Independent voices from the The Washington Times Communities
History doesn't have to be grim; there is a lot to be learned from the pages of time.
The Constitution: Every issue, every time. No exceptions, no excuses. And how to get from here to there.
Why can’t humans just be free to be humans?
Get in the middle of all the action inside and outside the boxing ring.
White House pets gone wild!